Literature DB >> 22619110

Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome.

Feng Li1, Yong-Ping Zhai, Yu-Mei Tang, Li-Ping Wang, Pin-Jun Wan.   

Abstract

The 8p11 myeloproliferative syndrome (EMS) is an aggressive neoplasm caused by the fusion of various partner genes to fibroblast growth factor receptor 1 (FGFR1). Various FGFR1 fusions are associated with subtly distinct disease phenotypes. Here, we report a new translocation at the FGFR1 locus in a patient who carried t(1;8)(q25;p11.2) and presented with myeloproliferative neoplasm-like symptoms. The patient was characterized by myeloid hyperplasia of bone marrow, markedly elevated numbers of monocytes, and normal to mildly elevated eosinophils. Initial fluorescent in situ hybridization analysis confirmed that FGFR1 in this patient was disrupted. Subsequent analysis led to the identification of a novel translocation, in which exon 23 of the translocated promoter region (TPR) gene at chromosome band 1q25 was fused to exon 13 of FGFR1 (RefSeq NM_0231102.2). The TPR portion of the fusion protein contains putative functional motifs including an N-terminal TprMet domain, nuclear pore complexes associating domain, and multiple coiled-coil domains. It is likely that one or more of the motifs from TPR contribute to dimerization, resulting in constitutive activation of the FGFR1 kinase domain. Our results further support a critical role of FGFR1 in the pathogenesis of EMS and may lead to more accurate diagnosis and potential targeted therapy.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22619110     DOI: 10.1002/gcc.21973

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

1.  Reply to the letter by Yang et al. RE: acute myeloid leukemia associated with FGFR1 abnormalities.

Authors:  Yonggoo Kim; Hyeyoung Lee; Myungshin Kim
Journal:  Int J Hematol       Date:  2013-06-05       Impact factor: 2.490

2.  Polymorphisms of FGFR1 in HBV-related hepatocellular carcinoma.

Authors:  Haiyang Xie; Chunyang Xing; Bajin Wei; Xiao Xu; Liming Wu; Jian Wu; Leiming Chen; Guoqiang Cao; Hai Chen; Xueqin Meng; Shengyong Yin; Lin Zhou; Shusen Zheng
Journal:  Tumour Biol       Date:  2015-06-12

3.  Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case.

Authors:  Christina B Duckworth; Linsheng Zhang; Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

Review 4.  Acute myeloid leukemia associated with FGFR1 abnormalities.

Authors:  Hyeyoung Lee; Myungshin Kim; Jihyang Lim; Yonggoo Kim; Kyungja Han; Byung-Sik Cho; Hee-Je Kim
Journal:  Int J Hematol       Date:  2013-04-23       Impact factor: 2.490

5.  A case of acute myelogenous leukaemia characterised by the BCR-FGFR1 translocation.

Authors:  Alexios Matikas; Ifigeneia Tzannou; Dimitra Oikonomopoulou; Maria Bakiri
Journal:  BMJ Case Rep       Date:  2013-03-20

Review 6.  Oncogenic potential of nucleoporins in non-hematological cancers: recent update beyond chromosome translocation and gene fusion.

Authors:  Adhiraj Roy; Gopeshwar Narayan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-25       Impact factor: 4.553

Review 7.  The Fibroblast Growth Factor signaling pathway.

Authors:  David M Ornitz; Nobuyuki Itoh
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-03-13       Impact factor: 5.814

8.  A novel fusion of SQSTM1 and FGFR1 in a patient with acute myelomonocytic leukemia with t(5;8)(q35;p11) translocation.

Authors:  Y Nakamura; Y Ito; N Wakimoto; E Kakegawa; Y Uchida; M Bessho
Journal:  Blood Cancer J       Date:  2014-12-12       Impact factor: 11.037

9.  Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion.

Authors:  Xu-Hua Qiu; Feng Li; Hong-Qin Cao; Jing-Jing Shao; Jian-Gang Mei; Han-Qing Li; Yong-Ping Zhai
Journal:  Mol Med Rep       Date:  2017-01-24       Impact factor: 2.952

10.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.

Authors:  Jinghui Zhang; Gang Wu; Claudia P Miller; Ruth G Tatevossian; James D Dalton; Bo Tang; Wilda Orisme; Chandanamali Punchihewa; Matthew Parker; Ibrahim Qaddoumi; Fredrick A Boop; Charles Lu; Cyriac Kandoth; Li Ding; Ryan Lee; Robert Huether; Xiang Chen; Erin Hedlund; Panduka Nagahawatte; Michael Rusch; Kristy Boggs; Jinjun Cheng; Jared Becksfort; Jing Ma; Guangchun Song; Yongjin Li; Lei Wei; Jianmin Wang; Sheila Shurtleff; John Easton; David Zhao; Robert S Fulton; Lucinda L Fulton; David J Dooling; Bhavin Vadodaria; Heather L Mulder; Chunlao Tang; Kerri Ochoa; Charles G Mullighan; Amar Gajjar; Richard Kriwacki; Denise Sheer; Richard J Gilbertson; Elaine R Mardis; Richard K Wilson; James R Downing; Suzanne J Baker; David W Ellison
Journal:  Nat Genet       Date:  2013-04-14       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.